Belgium-based radiotherapeutics company Full-Life Technologies USD $63.3M in funding. This round was co-led by Prosperity7 Ventures and an undisclosed healthcare specialist investor, along with new investors Sky9 Capital, Summer Capital, and GuanghuaWutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Junson Capital.
Read also – London-based Olsam Group Acquired Dwarfs
The $16 million loan facilities, secured in conjunction with the Series B equity financing, provide Full-Life with a flexible financing solution for the Company’s pipeline development and construction of the radiopharmaceutical manufacturing plant in Belgium.
Aysar Tayeb, Executive Managing Director of Prosperity7 Ventures said, “Cancer remains a formidable global challenge, causing immense suffering and loss, Full-Life is dedicated to addressing this issue within the field of Radionuclide Drug Conjugates (RDC) by leveraging its exceptional vector and linker design capabilities, as well as its expertise in radionuclides. Through its UniRDCTM platform, Full-Life has the potential to extend its therapeutic indications to a wider range of cancers. We eagerly anticipate the future advancements of Full-Life, as it strives to deliver differentiated and superior solutions that will significantly improve the outcomes and quality of life for cancer patients.”
Julie Wu, Chief Financial Officer of Full-Life said, “The financing reflects strong support from our new and existing investors of our strategy and faith in the significant progress we have made in just over two years to build a fully integrated radiopharmaceutical company, The funding will support our evolution into a clinical-stage company, the advancement of our pipeline programs, and the construction of a Good Manufacturing Practices (GMP) manufacturing facility.”
About Full-Life Technologies
Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. They seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients.
Read also – GLORY to Acquire Flooid